Antibacterial Activity of Ticagrelor in Conventional Antiplatelet Dosages Against Antibiotic-Resistant Gram-Positive Bacteria (Free)

Abstract

Ticagrelor reversibly inhibits the platelet adenosine diphosphate P2Y₁₂ receptor (P2Y₁₂).¹ It is approved for prevention of cardiovascular events in patients with atherosclerotic cardiovascular disease and shows evidence of superior clinical performance compared with other P2Y₁₂ inhibitors. A post hoc analysis of the Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome (PLATO) trial² revealed that patients treated with ticagrelor had a lower risk of infection-related death than those treated with clopidogrel bisulfate.³ More recently, in the Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor (XANTHIPPE) study, ticagrelor was associated with improved lung function in patients hospitalized for pneumonia.⁴ We therefore questioned whether ticagrelor or its metabolites could possess antimicrobial properties.